112 related articles for article (PubMed ID: 16014428)
1. Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures.
Schaumann R; Goldstein EJ; Forberg J; Rodloff AC
J Med Microbiol; 2005 Aug; 54(Pt 8):749-753. PubMed ID: 16014428
[TBL] [Abstract][Full Text] [Related]
2. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
[TBL] [Abstract][Full Text] [Related]
3. Activity of moxifloxacin, imipenem, and ertapenem against Escherichia coli, Enterobacter cloacae, Enterococcus faecalis, and Bacteroides fragilis in monocultures and mixed cultures in an in vitro pharmacokinetic/pharmacodynamic model simulating concentrations in the human pancreas.
Schubert S; Dalhoff A
Antimicrob Agents Chemother; 2012 Dec; 56(12):6434-6. PubMed ID: 23070164
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model.
Noel AR; Bowker KE; Macgowan AP
Antimicrob Agents Chemother; 2005 Oct; 49(10):4234-9. PubMed ID: 16189103
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.
Stearne LE; Kooi C; Goessens WH; Bakker-Woudenberg IA; Gyssens IC
Antimicrob Agents Chemother; 2001 Jan; 45(1):243-51. PubMed ID: 11120973
[TBL] [Abstract][Full Text] [Related]
6. Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli.
Schaumann R; Blatz R; Beer J; Ackermann G; Rodloff AC
J Antimicrob Chemother; 2004 Feb; 53(2):318-24. PubMed ID: 14729746
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of piperacillin/tazobactam and ertapenem against Bacteroides fragilis and Escherichia coli in pure and mixed cultures.
Valéria Dos Santos K; Diniz CG; Coutinho SC; Apolônio ACM; Geralda de Sousa-Gaia L; Nicoli JR; Farias LM; Roque de Carvalho MA
J Med Microbiol; 2007 Jun; 56(Pt 6):798-802. PubMed ID: 17510265
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.
Nielsen EI; Cars O; Friberg LE
Antimicrob Agents Chemother; 2011 Oct; 55(10):4619-30. PubMed ID: 21807983
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model.
Singh R; Ledesma KR; Chang KT; Hou JG; Prince RA; Tam VH
J Antimicrob Chemother; 2009 Sep; 64(3):556-62. PubMed ID: 19589810
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Anaerobic Pharmacokinetic/Pharmacodynamic Model to Simulate the Bactericidal Activity of Levornidazole Against Bacteroides fragilis.
Hu J; Zhang J; Chen Y; Liang W; Wu S
Clin Ther; 2017 Apr; 39(4):828-836. PubMed ID: 28363695
[TBL] [Abstract][Full Text] [Related]
12. Low endotoxin release from Escherichia coli and Bacteroides fragilis during exposure to moxifloxacin.
Trautmann M; Scheibe C; Wellinghausen N; Holst O; Lepper PM
Chemotherapy; 2010; 56(5):364-70. PubMed ID: 20926860
[TBL] [Abstract][Full Text] [Related]
13. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
Stass H; Dalhoff A
Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
[TBL] [Abstract][Full Text] [Related]
14. Reciprocal antimicrobial synergism between Escherichia coli and Bacteroides fragilis in the presence of metronidazole.
Soriano F; Ponte MC; Gaspar MC
J Clin Pathol; 1982 Oct; 35(10):1150-2. PubMed ID: 6752209
[TBL] [Abstract][Full Text] [Related]
15. Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus.
Lee SY; Fan HW; Sutherland C; DeRyke AC; Nicolau DP
Drugs R D; 2007; 8(2):69-77. PubMed ID: 17324004
[TBL] [Abstract][Full Text] [Related]
16. Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents.
Betriu C; Gómez M; Palau ML; Sánchez A; Picazo JJ
Antimicrob Agents Chemother; 1999 Sep; 43(9):2320-2. PubMed ID: 10471590
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.
Goldstein EJ; Citron DM; Warren YA; Tyrrell KL; Merriam CV; Fernandez H
Antimicrob Agents Chemother; 2006 Jan; 50(1):148-55. PubMed ID: 16377680
[TBL] [Abstract][Full Text] [Related]
18. Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.
Deshpande D; Srivastava S; Meek C; Leff R; Hall GS; Gumbo T
Antimicrob Agents Chemother; 2010 Jun; 54(6):2534-9. PubMed ID: 20385862
[TBL] [Abstract][Full Text] [Related]
19. Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997-2002).
Betriu C; Rodríguez-Avial I; Gómez M; Culebras E; Picazo JJ
Diagn Microbiol Infect Dis; 2005 Nov; 53(3):221-3. PubMed ID: 16243476
[TBL] [Abstract][Full Text] [Related]
20. In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.
Stearne LE; Gyssens IC; Goessens WH; Mouton JW; Oyen WJ; van der Meer JW; Verbrugh HA
Antimicrob Agents Chemother; 2001 May; 45(5):1394-401. PubMed ID: 11302801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
